OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 1,000 KRYS derivative securities | OQRO

Home
Insider trades
Krystal Biotech
Officer exercised or converted 1,000 KRYS derivative securities

Insider trades

Insider trade

Officer exercised or converted 1,000 KRYS derivative securities

Traded Jun 25, 2026 · Filed Jun 26, 2026

KRYKrystal BiotechKRYS

1,000
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 25, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 26, 2026

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0002114900-26-000009

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Jun 26, 2026, 10:45 PM UTC

Added to OQRO

Oct 6, 2026, 7:59 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Krystal Biotech, Inc.

Issuer CIK

1711279

Ticker

KRYS

Reporting person

John Charles Thomas

Relationship

Officer

Officer title

EVP, General Counsel

Security

Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Jun 25, 2026

Transaction code

Shares / units

1,000

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

6,500

Ownership form

Direct

Amendment

Footnotes from the filing

The options vest ratably over a four-year period beginning on February 28, 2026.

Around the same time

1,000Shares · @ $179.25

3mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record

Officer sold ~$347K of Krystal Biotech

Scheduled in advance3mo ago

Director sold ~$96K of Krystal Biotech

Scheduled in advance4mo ago